Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

doi:10.3390/ijerph17010210

. 2019 Dec 27;17(1):210.

doi: 10.3390/ijerph17010210.

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

Ya-Yen Yu^{1

2}, Shih-Ming Tsao^{3

4}, Wen-Ta Yang⁵, Wei-Chang Huang^{6

7

8

9}, Ching-Hsiung Lin¹⁰, Wei-Wen Chen¹¹, Shun-Fa Yang^{1

12}, Hui-Ling Chiou^{13

14}, Yi-Wen Huang^{1

11}

Affiliations

¹ Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
² Department of Clinical Laboratory, Changhua Hospital, Changhua 513, Taiwan.
³ Division of Chest, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
⁴ Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung 402, Taiwan.
⁵ Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung 403, Taiwan.
⁶ Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.
⁷ Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan.
⁸ Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan.
⁹ Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung 407, Taiwan.
¹⁰ Division of Chest, Changhua Christian Hospital, Changhua 500, Taiwan.
¹¹ Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan.
¹² Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
¹³ School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan.
¹⁴ Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan.

PMID: 31892222
PMCID: PMC6981901
DOI: 10.3390/ijerph17010210

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

Ya-Yen Yu et al. Int J Environ Res Public Health. 2019.

. 2019 Dec 27;17(1):210.

doi: 10.3390/ijerph17010210.

Authors

Ya-Yen Yu^{1

2}, Shih-Ming Tsao^{3

4}, Wen-Ta Yang⁵, Wei-Chang Huang^{6

7

8

9}, Ching-Hsiung Lin¹⁰, Wei-Wen Chen¹¹, Shun-Fa Yang^{1

12}, Hui-Ling Chiou^{13

14}, Yi-Wen Huang^{1

11}

Affiliations

¹ Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.
² Department of Clinical Laboratory, Changhua Hospital, Changhua 513, Taiwan.
³ Division of Chest, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
⁴ Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung 402, Taiwan.
⁵ Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung 403, Taiwan.
⁶ Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.
⁷ Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli 356, Taiwan.
⁸ Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan.
⁹ Department of Industrial Engineering and Enterprise Information, Tunghai University, Taichung 407, Taiwan.
¹⁰ Division of Chest, Changhua Christian Hospital, Changhua 500, Taiwan.
¹¹ Department of Health, Pulmonary and Critical Care Unit, Changhua Hospital, Changhua 500, Taiwan.
¹² Department of Medical Research, Chung Shan Medical University Hospital, Taichung 402, Taiwan.
¹³ School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 402, Taiwan.
¹⁴ Department of Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 402, Taiwan.

PMID: 31892222
PMCID: PMC6981901
DOI: 10.3390/ijerph17010210

Abstract

Weekly rifapentine and isoniazid therapy (3HP) is the most frequent treatment for latent tuberculosis infection (LTBI). However, the association between major adverse drug reactions (ADRs) and drug metabolic enzyme single-nucleotide polymorphisms (SNPs) remains unclear. In this study, 377 participants who received the 3HP regimen were recruited and examined for genotyping of CYP5A6, CYP2B6, CYP2C19, CYP2E1, and NAT2 SNPs. In our study, 184 participants (48.4%) developed ADRs. Moreover, CYP2C19 rs4986893 (TT vs. CC+CT, odds ratio [OR] [95% CI]: 2.231 [1.015-4.906]), CYP2E1 rs2070676 (CC vs. CG+GG, OR [95% CI]: 1.563 [1.022-2.389]), and CYP2E1 rs2515641 (CC vs. CT+TT, OR [95% CI]: 1.903 [1.250-2.898]) were associated with ADR development. In conclusion, CYP2C19 and CYP2E1 SNPs may provide useful information regarding ADRs in LTBI patients receiving the 3HP regimen.

Keywords: adverse drug reaction; drug metabolic enzymes; latent tuberculosis; polymorphism.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Cited by

Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid-Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study.
Rahman MT, Hossain F, Banu RS, Islam MS, Alam S, Faisel AJ, Salim H, Cordon O, Suarez P, Hussain H, Roy T. Rahman MT, et al. Trop Med Infect Dis. 2023 Dec 20;9(1):4. doi: 10.3390/tropicalmed9010004. Trop Med Infect Dis. 2023. PMID: 38276634 Free PMC article.
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.
Ulanova V, Kivrane A, Viksna A, Pahirko L, Freimane L, Sadovska D, Ozere I, Cirule A, Sevostjanovs E, Grinberga S, Bandere D, Ranka R. Ulanova V, et al. Front Pharmacol. 2024 Mar 22;15:1332752. doi: 10.3389/fphar.2024.1332752. eCollection 2024. Front Pharmacol. 2024. PMID: 38584604 Free PMC article.
Role of Militarine in PM_2.5-Induced BV-2 Cell Damage.
Tian SX, Cheng W, Lu JJ, Zhou FM, Ding ZS, Zhu BQ. Tian SX, et al. Neurochem Res. 2021 Jun;46(6):1423-1434. doi: 10.1007/s11064-021-03281-6. Epub 2021 Mar 6. Neurochem Res. 2021. PMID: 33675461
Impact of Age on Outcome of Rifapentine-Based Weekly Therapy for Latent Tuberculosis Infection.
Huang HL, Lee MR, Cheng MH, Lu PL, Huang CK, Sheu CC, Lai PC, Chen TC, Wang JY, Chong IW. Huang HL, et al. Clin Infect Dis. 2021 Sep 7;73(5):e1064-e1071. doi: 10.1093/cid/ciaa1741. Clin Infect Dis. 2021. PMID: 33215187 Free PMC article.
DRESS syndrome and tuberculosis: Implementation of a desensitization and re-desensitization protocol to recover antituberculosis drugs in a case series at a specialized TB Unit in Lima, Peru.
Morán-Mariños C, Llanos-Tejada F, Salas-Lopez J, Villanueva-Villegas R, Chavez-Huamani A, Vidal-Ruiz M, Rodriguez-Calienes A, Casanova-Mendoza R. Morán-Mariños C, et al. Medicine (Baltimore). 2024 Sep 27;103(39):e39365. doi: 10.1097/MD.0000000000039365. Medicine (Baltimore). 2024. PMID: 39331920 Free PMC article.

See all "Cited by" articles

References

1. Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. Who global surveillance and monitoring project. JAMA. 1999;282:677–686. doi: 10.1001/jama.282.7.677. - DOI - PubMed
1. Sterling T.R., Villarino M.E., Borisov A.S., Shang N., Gordin F., Bliven-Sizemore E., Hackman J., Hamilton C.D., Menzies D., Kerrigan A., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 2011;365:2155–2166. doi: 10.1056/NEJMoa1104875. - DOI - PubMed
1. Centers for Disease Control and Prevention (CDC) Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR. Morb. Mortal. Wkly. Rep. 2011;60:1650–1653. - PubMed
1. Doan T.N., Fox G.J., Meehan M.T., Scott N., Ragonnet R., Viney K., Trauer J.M., McBryde E.S. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: A decision analysis study. J. Antimicrob. Chemother. 2019;74:218–227. doi: 10.1093/jac/dky403. - DOI - PubMed
1. Bliven-Sizemore E.E., Sterling T.R., Shang N., Benator D., Schwartzman K., Reves R., Drobeniuc J., Bock N., Villarino M.E. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int. J. Tuberc. Lung Dis. 2015;19:1039–1044. doi: 10.5588/ijtld.14.0829. - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. Who global surveillance and monitoring project. JAMA. 1999;282:677–686. doi: 10.1001/jama.282.7.677. - DOI - PubMed

[2] Dye C., Scheele S., Dolin P., Pathania V., Raviglione M.C. Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. Who global surveillance and monitoring project. JAMA. 1999;282:677–686. doi: 10.1001/jama.282.7.677. - DOI - PubMed

[3] Sterling T.R., Villarino M.E., Borisov A.S., Shang N., Gordin F., Bliven-Sizemore E., Hackman J., Hamilton C.D., Menzies D., Kerrigan A., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 2011;365:2155–2166. doi: 10.1056/NEJMoa1104875. - DOI - PubMed

[4] Sterling T.R., Villarino M.E., Borisov A.S., Shang N., Gordin F., Bliven-Sizemore E., Hackman J., Hamilton C.D., Menzies D., Kerrigan A., et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 2011;365:2155–2166. doi: 10.1056/NEJMoa1104875. - DOI - PubMed

[5] Centers for Disease Control and Prevention (CDC) Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR. Morb. Mortal. Wkly. Rep. 2011;60:1650–1653. - PubMed

[6] Centers for Disease Control and Prevention (CDC) Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR. Morb. Mortal. Wkly. Rep. 2011;60:1650–1653. - PubMed

[7] Doan T.N., Fox G.J., Meehan M.T., Scott N., Ragonnet R., Viney K., Trauer J.M., McBryde E.S. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: A decision analysis study. J. Antimicrob. Chemother. 2019;74:218–227. doi: 10.1093/jac/dky403. - DOI - PubMed

[8] Doan T.N., Fox G.J., Meehan M.T., Scott N., Ragonnet R., Viney K., Trauer J.M., McBryde E.S. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: A decision analysis study. J. Antimicrob. Chemother. 2019;74:218–227. doi: 10.1093/jac/dky403. - DOI - PubMed

[9] Bliven-Sizemore E.E., Sterling T.R., Shang N., Benator D., Schwartzman K., Reves R., Drobeniuc J., Bock N., Villarino M.E. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int. J. Tuberc. Lung Dis. 2015;19:1039–1044. doi: 10.5588/ijtld.14.0829. - DOI - PMC - PubMed

[10] Bliven-Sizemore E.E., Sterling T.R., Shang N., Benator D., Schwartzman K., Reves R., Drobeniuc J., Bock N., Villarino M.E. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int. J. Tuberc. Lung Dis. 2015;19:1039–1044. doi: 10.5588/ijtld.14.0829. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

Affiliations

Association of Drug Metabolic Enzyme Genetic Polymorphisms and Adverse Drug Reactions in Patients Receiving Rifapentine and Isoniazid Therapy for Latent Tuberculosis

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Research Materials

Abstract

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Research Materials